Alendronate Review Article |
|
 |
|
 Alendronate belongs to the drug class known as biphosphonates. It slows bone loss and thus, is used for the treatment and prevention of osteoporosis which is also known as “the brittle bone disease” in post-menopausal women. It is also utilized to increase the bone mass of men who are suffering from osteoporosis. It is recommended for both women and men who have acquired a form of osteoporosis which is occasionally due to steroid medications, for instance prednisone. This drug is also used to mitigate pain caused by Paget’s disease of the bone which is a painful condition that deforms and weakens the bones. Alendronate is given daily or weekly. Its side effects may include ulceration of the esophagus, skin rash, and eye problems.
Alendronate is a drug classified as biphosphonates that is prescribed in treatment of bone disorders such as osteoporosis. Though it may be sold on its own, Alendronate is commonly marketed along with vitamin D which increases the absorption of the drug as well as helps in strengthening the bones. The patient group which mostly receives this drug is women in post menopausal age due to their bones becoming more and more fragile. In addition to this, Alendronate is prescribed for patients taking in steroids which have a negative effect on the bones. The drug may also be indicated to prevent bone diseases.
Alendronate has been compared to Risedronate which is another biphosphonate drug for bone disease prevention and cure. The study involved 383 women who were 6 to 35 months post menopausal of age. It consisted of the effectiveness of both trademark drugs in terms of prevention and treatment of postmenopausal osteoporosis while a second part involved 224 men and women from age 18 to 65 with osteoporosis caused by glucocorticoids. There was also a placebo group for control of the study which continued for 1 to 3 years. Level of efficacy in comparison to each other varied. While much of the significant changes in bone density for postmenopausal osteoporosis resulted from Alendronate, both drugs were tied in terms of safety and effectiveness for glucocorticoid-induced menopause. Continue reading...
| Dosage |
Packing |
Price |
Add to basket |
| 70 mg |
4 tab |
USD 47.00 |
 |
On another clinical trial, Aledronate was compared to Pamidronate which was also under the same class and for the same use on osteoporosis. However, on this study, both drugs were tested for Paget’s disease of the bone which was a chronic condition causing abnormal enlargement and deformation of certain bones. Both of these drugs are considered second and third generation biphosphonates medications for Paget’s disease of the bone and are preferable than the previous drugs calcitonin and etidronate for treatment.
To determine which of these drugs is better, researchers used a 2 year randomized clinical trial for 72 subjects with the bone disease. They were then randomly assigned to either take oral Alendronate, intravenous Pamidronate or placebo. A certain key factor in this study though, was that there was a group which has already been previously treated with Pamidronate alone. The subjects were to receive either Pamidronate in a single infusion or Alendronate in a dosage of 40 mg per day. ALP and urine deoxypyridinoline/ creatinine ratio was monitored to determine for biochemical remission. Over time, they found that both drugs have almost the same level of effectiveness for biochemical remission but Alendronate had more efficacy in achieving this on patients who have been previously treated with the other drug.
References:
1. Peters ML, Leonard M, Licata AA. 2001. Role of Alendronate and Risedronate in Preventing and Treating Osteoporosis. Cleve Clin J Med 68:945-951.
2. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH. 2004. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone, 34(4):747-54.
|
|
Bone resorption inhibitor
 Alendronate Review Article
Buy here
|
|
My Basket
